ENKLA-MNCT07249476
Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia
At risk: Primary completion moved 6 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Jun 1, 2029 to Dec 1, 2029
- Start date: Jun 1, 2026 to Dec 1, 2026
- Eligibility criteria expanded, about 9 words
- Study completion pushed from Jun 1, 2030 to Dec 1, 2030
- Minor Study sites: 0 to 1v4
- Notable Start date: Feb 1, 2026 to Jun 1, 2026
- Primary completion date: Feb 1, 2029 to Jun 1, 2029
- Study completion date: Feb 1, 2030 to Jun 1, 2030
- Notable Eligibility criteria expanded, about 2 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
\> 20 Acute myeloid leukaemia/myelodysplastic syndrome patients receiving a matched transplant: 10 patients receiving AZA/DLI for relapse prevention. 10 patients not receiving AZA/DLI (control group). This group is monitored at diagnosis and for 12 months after transplantation.
\> 20 Acute myeloid leukaemia/myelodysplastic syndrome patients receiving a haploidentical transplant: 10 patients receiving AZA/DLI for relapse prevention. 10 patients not receiving AZA/DLI (control group). This group is monitored at diagnosis and for 12 months after transplantation.
10 Patients with a (Acute lymphoblastic leukaemia). This group is monitored at diagnosis only.
Other: Bone marrow sampling (during routine care), Blood samples (during routine care)
Sites
1 site in 1 country
- CHU de NantesNantes, France